Luma Therapeutics closes first equity round, has patent approved, wins pitch competition

Congratulations to Luma Therapeutics--a finalist in 2015's primeUC competition. Founder and CEO Evan Anderson told us that the company had closed an equity round of $750K to get them through their market-based clinical trial and regulatory clearance.

Evan also said that Luma's patent protecting its hydrogel technology was granted by the USPTO.

And Luma recently took first prize at the Derm Entrepreneurship Conference.

Keep up the good work, Luma!